• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Herbalife Reports Second Quarter 2024 Results, Adjusted EBITDA1 Exceeds Guidance; Raised Full-Year Adjusted EBITDA1 Guidance

    7/31/24 4:10:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care
    Get the next $HLF alert in real time by email

    Herbalife Ltd. (NYSE:HLF) today reported financial results for the second quarter ended June 30, 2024:

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730118998/en/

    "Our Q2 Adjusted EBITDA1 is the highest it's been in seven quarters. We remain focused on driving shareholder value as the continued increase in new distributors builds the foundation for sales growth." - Michael Johnson, Chairman and CEO

    Highlights

    Second Quarter 2024

    • Net sales of $1.3 billion, down 2.5% vs. Q2 '23 due to 270 basis points of FX headwinds
      • Achieved year-over-year net sales growth on constant currency basis2, up 0.2%, driven by increases in Latin America, EMEA and Asia Pacific
    • Net income of $4.7 million; adjusted net income1 of $54.8 million
    • Adjusted EBITDA1 of $180.0 million exceeds guidance; adjusted EBITDA1 margin up 120 basis points year-over-year
    • Diluted EPS of $0.05; adjusted diluted EPS1 of $0.54
      • Restructuring Program expenses, net of tax, $0.33 diluted EPS headwind; excluded from adjusted results
      • Loss on extinguishment of debt, net of tax, $0.07 diluted EPS headwind; excluded from adjusted results
    • Net cash provided by operating activities of $102.5 million; capital expenditures of approximately $36 million
    • Credit Agreement EBITDA1 $208.0 million; total leverage ratio reduced to 3.5x at June 30

    Recent Developments

    • Completed sale and sixteen-month leaseback of office building in Torrance, California in July

    Outlook

    • Third quarter 2024 guidance provided
    • Full-year 2024 guidance revised: net sales reduced, adjusted EBITDA1 raised, capital expenditures reaffirmed

    _________________________

    1 Non-GAAP measure. Refer to Schedule A – "Reconciliation of Non-GAAP Financial Measures" for a detailed reconciliation of these measures to the most directly comparable U.S. GAAP measure for historical periods, as applicable, and a discussion of why the Company believes these non-GAAP measures are useful and certain information regarding non-GAAP guidance.

    2 Growth/decline in net sales excluding the effects of foreign exchange is based on "net sales in local currency," a non-GAAP financial measure. Refer to Schedule A – "Reconciliation of Non-GAAP Financial Measures" for a discussion of why the Company believes adjusting for the effects of foreign exchange is useful.

    Management Commentary

    Herbalife reported second quarter 2024 net sales of $1.3 billion, down 2.5% year-over-year, including 270 basis points of foreign currency headwinds. On a constant currency basis2, net sales increased 0.2% year-over-year.

    Second quarter gross profit margin improved to 77.9% compared to 77.0% in the second quarter of 2023. On a year-over-year basis, gross profit margin primarily benefited from approximately 160 basis points of pricing, partially offset by approximately 60 basis points of input cost inflation, mainly related to increased raw material costs.

    Net income was $4.7 million, with net income margin of 0.4% and adjusted net income1 of $54.8 million. Adjusted EBITDA1 of $180.0 million includes approximately $11 million of foreign currency headwinds year-over-year, with adjusted EBITDA1 margin of 14.1%, up 120 basis points year-over-year. Diluted EPS was $0.05, with adjusted diluted EPS1 of $0.54, which includes a $0.07 year-over-year foreign currency headwind.

    Net cash provided by operating activities was $102.5 million and $116.3 million for the three and six months ended June 30, 2024, respectively. Capital expenditures were approximately $36 million and $69 million for the three and six months ended June 30, 2024, respectively, and capitalized SaaS implementation costs were approximately $5 million and $10 million, respectively. The Company expects to incur total capital expenditures of approximately $120 million to $150 million and total capitalized SaaS implementation costs of approximately $20 million to $25 million for the full year of 2024.

    The Company implemented further actions related to its Restructuring Program, which was initiated during the first quarter of 2024 and designed to bring leadership closer to its markets, streamline the employee structure and accelerate productivity. The Restructuring Program is expected to deliver annual savings of at least $80 million beginning in 2025, with at least $50 million now expected to be achieved in 2024 (up from approximately $40 million). Based on actions through June 30, at least $10 million of savings were realized during the second quarter of 2024. The Company expects to incur total program pre-tax expenses of approximately $70 million (up from at least $60 million) related to the program, which are primarily related to severance costs and will be excluded from adjusted results. For the three and six months ended June 30, 2024, approximately $49 million and $66 million of pre-tax expenses were recognized in SG&A related to the restructuring. Substantially all actions related to the program have been completed as of June 30, with the remainder to be completed by the end of 2024.

    As previously disclosed, the Company completed a $1.6 billion debt refinancing in April, which included $1.2 billion of senior secured debt and a $400 million senior secured revolving credit facility. Proceeds from the transactions were used to repay all amounts outstanding under the 2018 Credit Facility, which were scheduled to mature in 2025, and redeem $300 million of the $600 million aggregate principal amount of the 2025 Notes. In addition, the Company separately repurchased approximately $38 million of the 2025 Notes in a private transaction in April. For the three months ended June 30, 2024, a $10.5 million loss on extinguishment of debt related to the transactions was recognized in other expense, net and is excluded from adjusted results.

    In July, the Company completed the sale and a sixteen-month leaseback transaction of its office building in Torrance, California. The net proceeds from the sale transaction were approximately $38 million. The Company expects to recognize a gain of approximately $4 million related to the sale in SG&A in the third quarter of 2024, which will be excluded from adjusted results.

    "We continue to make significant progress in our initiatives to enhance profitability," said John DeSimone, Chief Financial Officer. "We remain focused on further expanding margins, creating shareholder value and reducing our total leverage ratio to 3.0x by the end of 2025."

    Over the past three months, approximately 83,300 attendees from around the world convened at Extravaganza training events in Thailand, Colombia, India and the U.S. The Asia Pacific region set a new attendance record in Bangkok with approximately 24,000 attendees present. India held its first-ever multi-city Extravaganza with events in both Bangalore and Delhi, collectively setting a new record with approximately 35,700 attendees.

    For the second quarter of 2024, the number of new distributors joining Herbalife worldwide increased 12% year-over-year and 26% on a sequential basis, reversing 12 consecutive quarters of year-over-year declines. The Company believes events such as Extravaganzas, access to industry-leading entrepreneurial skills training, as well as the March 2024 launch of the all-new Herbalife Premier League training and recognition program, which is designed to encourage recruitment and activity from new distributors, are driving the positive momentum in new distributor recruiting.

    "This is an exciting time at Herbalife and while we have work to do, there are many good things happening," said Michael Johnson. "Our Adjusted EBITDA1 margins are up, we've reduced our total leverage ratio to 3.5x, distributor recruiting is up and distributors are engaged in building their businesses."

    Second Quarter and Year to Date 2024 Key Metrics

    Regional Net Sales and Foreign Exchange ("FX") Impact

     

    Reported Net Sales

     

    YoY Growth (Decline)

     

    $ million

    Q2 ‘24

    Q2 ‘23

     

    including FX

    excluding FX2

    North America

    $

    283.2

    $

    303.6

     

    (6.7

    )%

    (6.7

    )%

    Latin America

     

    211.7

     

    207.0

     

    2.3

    %

    4.7

    %

    EMEA

     

    287.8

     

    289.6

     

    (0.6

    )%

    3.5

    %

    Asia Pacific

     

    416.7

     

    425.8

     

    (2.1

    )%

    1.6

    %

    China

     

    81.7

     

    88.0

     

    (7.2

    )%

    (4.0

    )%

    Worldwide

    $

    1,281.1

    $

    1,314.0

     

    (2.5

    )%

    0.2

    %

     

    Reported Net Sales

     

    YoY Growth (Decline)

     

    $ million

    YTD ‘24

    YTD ‘23

     

    including FX

    excluding FX2

    North America

    $

    549.0

    $

    600.8

     

    (8.6

    )%

    (8.6

    )%

    Latin America

     

    425.9

     

    412.5

     

    3.2

    %

    3.3

    %

    EMEA

     

    565.7

     

    557.7

     

    1.4

    %

    4.9

    %

    Asia Pacific

     

    847.9

     

    839.4

     

    1.0

    %

    4.2

    %

    China

     

    156.9

     

    155.7

     

    0.8

    %

    5.0

    %

    Worldwide

    $

    2,545.4

    $

    2,566.1

     

    (0.8

    )%

    1.3

    %

    Regional Volume Point Metrics

     

    Volume Points

    in millions

    Q2 ‘24

    Q2 ‘23

    YoY % Chg.

     

    YTD ‘24

    YTD ‘23

    YoY % Chg.

    North America

    272.5

    313.4

    (13.1

    )%

     

    536.7

    627.9

    (14.5

    )%

    Latin America(a)

    253.2

    258.5

    (2.1

    )%

     

    508.5

    529.9

    (4.0

    )%

    EMEA

    299.2

    331.2

    (9.7

    )%

     

    597.9

    645.5

    (7.4

    )%

    Asia Pacific

    520.2

    530.5

    (1.9

    )%

     

    1,048.6

    1,035.7

    1.2

    %

    China

    61.5

    62.6

    (1.8

    )%

     

    116.3

    111.2

    4.6

    %

    Worldwide(b)

    1,406.6

    1,496.2

    (6.0

    )%

     

    2,808.0

    2,950.2

    (4.8

    )%

    Note: During Q2 ‘24, most markets within the Latin America region, excluding Mexico, implemented a 5% price reduction and Volume Point adjustments to enhance the competitiveness of product pricing, aiming to stimulate incremental volume growth and increase Members' ability to promote business opportunities. Refer to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 for additional details.

    (a)

    Excluding the Volume Point adjustments noted above, the year-over-year percentage change for Q2 '24 and YTD ‘24 would have been a decrease of 3.5% and 4.8%, respectively.

    (b)

    Excluding the Volume Point adjustments noted above, the year-over-year percentage change for Q2 '24 and YTD ‘24 would have been a decrease of 6.2% and 5.0%, respectively.

    Outlook

    Third Quarter 2024 Guidance

     

    $ million

    Q3 ‘24 Guidance

    Q3 ‘23 Results

    Net Sales

    (4.5)% to 0% YoY

    1,281.3

    Adjusted EBITDA1

    125 – 155

    163.3

    Capital Expenditures

    35 – 45

    31.1

    Full-Year 2024 Guidance – Revised

     

    $ million

    FY ‘24 Guidance

    REVISED

     

    FY ‘24 Guidance

    (as of May 1 '24)

    FY ‘23 Results

    Net Sales

    (3.5)% to +1.5% YoY

    Reduced

    0% to +5% YoY

    5,062.4

    Adjusted EBITDA1

    560 – 600

    Raised

    550 – 590

    570.6

    Capital Expenditures

    120 – 150

    Reaffirmed

    120 – 150

    135.0

    Earnings Webcast and Conference Call

    Herbalife's senior management team will host a live audio webcast and conference call to discuss its second quarter 2024 financial results on Wednesday, July 31, 2024, at 5:30 p.m. ET (2:30 p.m. PT).

    The live audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/ebzt6ttw.

    Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link: https://register.vevent.com/register/BI912a2bd326f64fcfb80efc4f2f34d208.

    Senior management also plans to reference slides during the webcast and call, which will be available under the Investor Relations section of Herbalife's website at https://ir.herbalife.com, where financial and other information is posted from time to time. The live webcast will also be available at the same website, along with a replay of the webcast following the completion of the event and for 12 months thereafter.

    About Herbalife Ltd.

    Herbalife (NYSE:HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.

    For more information, visit https://ir.herbalife.com.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operations, capital expenditures, or share repurchases; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief or expectation; and any statements of assumptions underlying any of the foregoing or other future events. Forward-looking statements may include, among others, the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "anticipate" or any other similar words.

    Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following:

    • the potential impacts of current global economic conditions, including inflation, on us; our Members, customers, and supply chain; and the world economy;
    • our ability to attract and retain Members;
    • our relationship with, and our ability to influence the actions of, our Members;
    • our noncompliance with, or improper action by our employees or Members in violation of, applicable U.S. and foreign laws, rules, and regulations;
    • adverse publicity associated with our Company or the direct-selling industry, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws;
    • changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance, or ESG, matters;
    • the competitive nature of our business and industry;
    • legal and regulatory matters, including regulatory actions concerning, or legal challenges to, our products or network marketing program and product liability claims;
    • the Consent Order entered into with the Federal Trade Commission, or FTC, the effects thereof and any failure to comply therewith;
    • risks associated with operating internationally and in China;
    • our ability to execute our growth and other strategic initiatives, including implementation of our restructuring initiatives, and increased penetration of our existing markets;
    • any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, including the war in Ukraine, cybersecurity incidents, pandemics, and/or other acts by third parties;
    • our ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute our products;
    • our reliance on our information technology infrastructure;
    • noncompliance by us or our Members with any privacy laws, rules, or regulations or any security breach involving the misappropriation, loss, or other unauthorized use or disclosure of confidential information;
    • contractual limitations on our ability to expand or change our direct-selling business model;
    • the sufficiency of our trademarks and other intellectual property;
    • product concentration;
    • our reliance upon, or the loss or departure of any member of, our senior management team;
    • restrictions imposed by covenants in the agreements governing our indebtedness;
    • risks related to our convertible notes;
    • changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation;
    • our incorporation under the laws of the Cayman Islands; and
    • share price volatility related to, among other things, speculative trading and certain traders shorting our common shares.

    Additional factors and uncertainties that could cause actual results or outcomes to differ materially from our forward-looking statements are set forth in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, filed with the Securities and Exchange Commission on July 31, 2024, including under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in our Condensed Consolidated Financial Statements and the related Notes included therein, and Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 14, 2024, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in our Consolidated Financial Statements and the related Notes included therein. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future.

    Forward-looking statements made in this release speak only as of the date hereof. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

    Results of Operations

    Herbalife Ltd. and Subsidiaries
    Condensed Consolidated Statements of Income
    (in millions, except per share amounts)
     
     
    Three Months Ended June 30, Six Months Ended June 30,

    2024

    2023

    2024

    2023

    (unaudited)

    North America

    $

    283.2

    $

    303.6

     

    $

    549.0

    $

    600.8

     

    Latin America

     

    211.7

     

    207.0

     

     

    425.9

     

    412.5

     

    EMEA

     

    287.8

     

    289.6

     

     

    565.7

     

    557.7

     

    Asia Pacific

     

    416.7

     

    425.8

     

     

    847.9

     

    839.4

     

    China

     

    81.7

     

    88.0

     

     

    156.9

     

    155.7

     

    Worldwide Net sales

     

    1,281.1

     

    1,314.0

     

     

    2,545.4

     

    2,566.1

     

    Cost of sales

     

    283.1

     

    301.6

     

     

    568.1

     

    600.2

     

    Gross profit

     

    998.0

     

    1,012.4

     

     

    1,977.3

     

    1,965.9

     

    Royalty overrides

     

    415.3

     

    429.7

     

     

    830.5

     

    845.7

     

    Selling, general, and administrative expenses

     

    502.3

     

    460.5

     

     

    994.5

     

    936.4

     

    Other operating income (1)

     

    -

     

    (1.2

    )

     

    -

     

    (10.1

    )

    Operating income

     

    80.4

     

    123.4

     

     

    152.3

     

    193.9

     

    Interest expense, net

     

    57.7

     

    38.4

     

     

    95.6

     

    77.8

     

    Other expense, net (2)

     

    10.5

     

    -

     

     

    10.5

     

    -

     

    Income before income taxes

     

    12.2

     

    85.0

     

     

    46.2

     

    116.1

     

    Income taxes

     

    7.5

     

    25.1

     

     

    17.2

     

    26.9

     

    Net income

    $

    4.7

    $

    59.9

     

    $

    29.0

    $

    89.2

     

     
    Weighted-average shares outstanding:
    Basic

     

    100.6

     

    99.1

     

     

    100.1

     

    98.8

     

    Diluted

     

    101.7

     

    99.5

     

     

    101.2

     

    99.8

     

     
    Earnings per share:
    Basic

    $

    0.05

    $

    0.60

     

    $

    0.29

    $

    0.90

     

    Diluted

    $

    0.05

    $

    0.60

     

    $

    0.29

    $

    0.89

     

     

    (1) Other operating income for the three and six months ended June 30, 2023 relates to certain China government grant income

    (2) Other expense, net for the three and six months ended June 30, 2024 relates to loss on extinguishment of 2018 Credit Facility, as well as partial redemption and private repurchase of 2025 Notes
     
    Herbalife Ltd. and Subsidiaries
    Condensed Consolidated Balance Sheets
    (in millions)
     
    June 30, December 31,

    2024

    2023

    (unaudited)
    ASSETS
    Current Assets:
    Cash and cash equivalents

    $

    374.0

     

    $

    575.2

     

    Receivables, net

     

    82.8

     

     

    81.2

     

    Inventories

     

    480.7

     

     

    505.2

     

    Prepaid expenses and other current assets

     

    276.3

     

     

    237.7

     

    Total Current Assets

     

    1,213.8

     

     

    1,399.3

     

     
    Property, plant and equipment, net

     

    468.2

     

     

    506.5

     

    Operating lease right-of-use assets

     

    188.3

     

     

    185.8

     

    Marketing-related intangibles and other intangible assets, net

     

    313.1

     

     

    314.0

     

    Goodwill

     

    91.5

     

     

    95.4

     

    Other assets

     

    327.3

     

     

    308.4

     

    Total Assets

    $

    2,602.2

     

    $

    2,809.4

     

     
    LIABILITIES AND SHAREHOLDERS' DEFICIT
    Current Liabilities:
    Accounts payable

    $

    81.3

     

    $

    84.0

     

    Royalty overrides

     

    316.5

     

     

    343.4

     

    Current portion of long-term debt

     

    21.7

     

     

    309.5

     

    Other current liabilities

     

    556.7

     

     

    540.7

     

    Total Current Liabilities

     

    976.2

     

     

    1,277.6

     

     
    Non-current liabilities:
    Long-term debt, net of current portion

     

    2,321.0

     

     

    2,252.9

     

    Non-current operating lease liabilities

     

    173.3

     

     

    167.6

     

    Other non-current liabilities

     

    168.9

     

     

    171.6

     

    Total Liabilities

     

    3,639.4

     

     

    3,869.7

     

     
    Commitments and Contingencies
     
    Shareholders' deficit:
    Common shares

     

    0.1

     

     

    0.1

     

    Paid-in capital in excess of par value

     

    253.4

     

     

    233.9

     

    Accumulated other comprehensive loss

     

    (257.4

    )

     

    (232.0

    )

    Accumulated deficit

     

    (1,033.3

    )

     

    (1,062.3

    )

    Total Shareholders' Deficit

     

    (1,037.2

    )

     

    (1,060.3

    )

     
    Total Liabilities and Shareholders' Deficit

    $

    2,602.2

     

    $

    2,809.4

     

     
    Herbalife Ltd. and Subsidiaries
    Condensed Consolidated Statements of Cash Flows
    (in millions)
     
    Six Months Ended June 30,

    2024

    2023

    (unaudited)
    Cash flows from operating activities:
    Net income

    $

    29.0

     

    $

    89.2

     

    Adjustments to reconcile net income to net cash provided by operating activities:
    Depreciation and amortization

     

    61.8

     

     

    56.7

     

    Share-based compensation expenses

     

    23.7

     

     

    22.0

     

    Non-cash interest expense

     

    5.6

     

     

    3.6

     

    Deferred income taxes

     

    (27.5

    )

     

    (8.4

    )

    Inventory write-downs

     

    11.4

     

     

    16.9

     

    Foreign exchange transaction loss (gain)

     

    4.5

     

     

    1.0

     

    Loss on extinguishment of debt

     

    10.5

     

     

    -

     

    Other

     

    2.8

     

     

    3.4

     

    Changes in operating assets and liabilities:
    Receivables

     

    (5.1

    )

     

    (16.6

    )

    Inventories

     

    (6.6

    )

     

    50.7

     

    Prepaid expenses and other current assets

     

    (6.4

    )

     

    (17.5

    )

    Accounts payable

     

    (3.5

    )

     

    (0.8

    )

    Royalty overrides

     

    (19.2

    )

     

    (21.3

    )

    Other current liabilities

     

    41.2

     

     

    15.3

     

    Other

     

    (5.9

    )

     

    (12.4

    )

    Net cash provided by operating activities

     

    116.3

     

     

    181.8

     

     
    Cash flows from investing activities:
    Purchases of property, plant and equipment

     

    (69.2

    )

     

    (68.6

    )

    Other

     

    0.2

     

     

    0.1

     

    Net cash used in investing activities

     

    (69.0

    )

     

    (68.5

    )

     
    Cash flows from financing activities:
    Borrowings from senior secured credit facility and other debt

     

    961.7

     

     

    71.0

     

    Principal payments on senior secured credit facility and other debt

     

    (1,413.8

    )

     

    (146.7

    )

    Repayment of convertible senior notes

     

    (197.0

    )

     

    -

     

    Proceeeds from senior secured notes, net of discount

     

    778.4

     

     

    -

     

    Repayment of senior notes

     

    (344.3

    )

     

    -

     

    Debt issuance costs

     

    (20.9

    )

     

    (1.8

    )

    Share repurchases

     

    (5.7

    )

     

    (9.4

    )

    Other

     

    1.4

     

     

    1.6

     

    Net cash used in financing activities

     

    (240.2

    )

     

    (85.3

    )

    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

     

    (13.3

    )

     

    3.0

     

    Net change in cash, cash equivalents, and restricted cash

     

    (206.2

    )

     

    31.0

     

    Cash, cash equivalents, and restricted cash, beginning of period

     

    595.5

     

     

    516.3

     

    Cash, cash equivalents, and restricted cash, end of period

    $

    389.3

     

    $

    547.3

     

     

    Supplemental Information

    SCHEDULE A: RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (unaudited)

    Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA and Credit Agreement EBITDA

    In addition to its reported results calculated in accordance with U.S. GAAP, the Company has included in this release adjusted net income, adjusted diluted EPS, adjusted EBITDA and credit agreement EBITDA, performance measures that the Securities and Exchange Commission defines as "non-GAAP financial measures." Adjusted net income, adjusted diluted EPS, adjusted EBITDA and credit agreement EBITDA exclude the impact of certain unusual or non-recurring items such as expenses related to restructuring initiatives, expenses related to the digital technology program, gains or losses from extinguishment of debt and Korea tax settlement, as further detailed in the reconciliations below. Adjusted EBITDA margin represents adjusted EBITDA divided by net sales. Credit agreement EBITDA represents EBITDA adjusted for certain items permitted under our senior secured credit facilities.

    Management believes that such non-GAAP performance measures, when read in conjunction with the Company's reported results, calculated in accordance with U.S. GAAP, can provide useful supplemental information for investors because they facilitate a period to period comparative assessment of the Company's operating performance relative to its performance based on reported results under U.S. GAAP, while isolating the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance.

    The Company's definitions and calculations as set forth in the tables below of adjusted net income, adjusted diluted EPS, adjusted EBITDA and credit agreement EBITDA may not be comparable to similarly titled measures used by other companies because other companies may not calculate them in the same manner as the Company does and should not be viewed in isolation from, nor as alternatives to, net income or diluted EPS calculated in accordance with U.S. GAAP.

    The Company does not provide a reconciliation of forward-looking adjusted EBITDA guidance to net income, the comparable U.S. GAAP measure, because, due to the unpredictable or unknown nature of certain significant items, such as income tax expenses or benefits, loss contingencies, and any gains or losses in connection with refinancing transactions, we cannot reconcile this non-GAAP projection without unreasonable efforts. We expect the variability of these items, which are necessary for a presentation of the reconciliation, could have a significant impact on our reported U.S. GAAP financial results.

    Currency Fluctuation

    Our international operations have provided and will continue to provide a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the U.S. dollar against foreign currencies. In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, in addition to comparing the percent change in net sales from one period to another in U.S. dollars, we also compare the percent change in net sales from one period to another period using "net sales in local currency." Net sales in local currency is not a measure presented in accordance with U.S. GAAP. Net sales in local currency removes from net sales in U.S. dollars the impact of changes in exchange rates between the U.S. dollar and the local currencies of our foreign subsidiaries, by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period. We believe presenting net sales in local currency is useful to investors because it allows a meaningful comparison of net sales of our foreign operations from period to period. However, net sales in local currency should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

    The following is a reconciliation of net income to adjusted net income:

    Three Months Ended June 30, Six Months Ended June 30,
    $ million

    2024

    2023

    2024

    2023

    Net income

    $

    4.7

     

    $

    59.9

     

    $

    29.0

     

    $

    89.2

     

    Expenses related to Restructuring Program (1) (2)

     

    48.8

     

     

    -

     

     

    65.5

     

     

    -

     

    Expenses related to Transformation Program (1) (2)

     

    3.5

     

     

    10.1

     

     

    9.4

     

     

    37.4

     

    Digital technology program costs (1) (2)

     

    6.0

     

     

    7.0

     

     

    17.0

     

     

    10.5

     

    Loss on extinguishment of debt (1) (2)

     

    10.5

     

     

    -

     

     

    10.5

     

     

    -

     

    Income tax adjustments for above items (1) (2)

     

    (18.7

    )

     

    (3.0

    )

     

    (27.3

    )

     

    (9.2

    )

    Adjusted net income

    $

    54.8

     

    $

    74.0

     

    $

    104.1

     

    $

    127.9

     

     

    The following is a reconciliation of diluted earnings per share to adjusted diluted earnings per share:

    Three Months Ended June 30, Six Months Ended June 30,
    $ per share

    2024

    2023

    2024

    2023

    Diluted earnings per share

    $

    0.05

     

    $

    0.60

     

    $

    0.29

     

    $

    0.89

     

    Expenses related to Restructuring Program (1) (2)

     

    0.48

     

     

    -

     

     

    0.65

     

     

    -

     

    Expenses related to Transformation Program (1) (2)

     

    0.03

     

     

    0.10

     

     

    0.09

     

     

    0.37

     

    Digital technology program costs (1) (2)

     

    0.06

     

     

    0.07

     

     

    0.17

     

     

    0.11

     

    Loss on extinguishment of debt (1) (2)

     

    0.10

     

     

    -

     

     

    0.10

     

     

    -

     

    Income tax adjustments for above items (1) (2)

     

    (0.18

    )

     

    (0.03

    )

     

    (0.27

    )

     

    (0.09

    )

    Adjusted diluted earnings per share

    $

    0.54

     

    $

    0.74

     

    $

    1.03

     

    $

    1.28

     

     

    The following is a reconciliation of net income to EBITDA, adjusted EBITDA and Credit Agreement EBITDA and Credit Agreement total leverage ratio:

    Three Months Ended TTM
    $ million Jun 30 '23 Sep 30 '23 Dec 31 '23 Mar 31 '24 Jun 30 '24 Jun 30 '24
    Net sales

    $

    1,314.0

     

    $

    1,281.3

     

    $

    1,215.0

     

    $

    1,264.3

     

    $

    1,281.1

     

    $

    5,041.7

     

     
    Net income

    $

    59.9

     

    $

    42.8

     

    $

    10.2

     

    $

    24.3

     

    $

    4.7

     

    $

    82.0

     

    Interest expense, net

     

    38.4

     

     

    38.5

     

     

    38.1

     

     

    37.9

     

     

    57.7

     

     

    172.2

     

    Income taxes

     

    25.1

     

     

    26.4

     

     

    7.5

     

     

    9.7

     

     

    7.5

     

     

    51.1

     

    Depreciation and amortization

     

    29.1

     

     

    28.4

     

     

    28.2

     

     

    29.2

     

     

    32.6

     

     

    118.4

     

    EBITDA

     

    152.5

     

     

    136.1

     

     

    84.0

     

     

    101.1

     

     

    102.5

     

     

    423.7

     

    Amortization of SaaS implementation costs

     

    -

     

     

    2.9

     

     

    3.1

     

     

    3.6

     

     

    8.7

     

     

    18.3

     

    Expenses related to Restructuring Program

     

    -

     

     

    -

     

     

    -

     

     

    16.7

     

     

    48.8

     

     

    65.5

     

    Expenses related to Transformation Program

     

    10.1

     

     

    4.6

     

     

    12.2

     

     

    5.9

     

     

    3.5

     

     

    26.2

     

    Digital technology program costs

     

    7.0

     

     

    12.1

     

     

    9.5

     

     

    11.0

     

     

    6.0

     

     

    38.6

     

    (Gain) loss on extinguishment of debt

     

    -

     

     

    (1.0

    )

     

    -

     

     

    -

     

     

    10.5

     

     

    9.5

     

    Korea tax settlement

     

    -

     

     

    8.6

     

     

    -

     

     

    -

     

     

    -

     

     

    8.6

     

    Adjusted EBITDA

    $

    169.6

     

    $

    163.3

     

    $

    108.8

     

    $

    138.3

     

    $

    180.0

     

    $

    590.4

     

    Adjusted EBITDA margin

     

    12.9

    %

     

    12.7

    %

     

    9.0

    %

     

    10.9

    %

     

    14.1

    %

     

    11.7

    %

     
    Interest income

     

    2.7

     

     

    3.2

     

     

    3.2

     

     

    3.7

     

     

    2.8

     

     

    12.9

     

    Inventory write-downs

     

    5.4

     

     

    5.0

     

     

    6.6

     

     

    4.7

     

     

    6.7

     

     

    23.0

     

    Share-based compensation expenses

     

    11.2

     

     

    13.7

     

     

    12.3

     

     

    11.9

     

     

    11.8

     

     

    49.7

     

    Other expenses (3)

     

    (1.2

    )

     

    (3.8

    )

     

    11.8

     

     

    0.9

     

     

    6.7

     

     

    15.6

     

    Credit Agreement EBITDA

    $

    187.7

     

    $

    181.4

     

    $

    142.7

     

    $

    159.5

     

    $

    208.0

     

    $

    691.6

     

    Credit Agreement Total Debt (4)

    $

    2,422.5

     

    Credit Agreement Total Leverage Ratio 3.5x
     

    The following is a reconciliation of net income to EBITDA, adjusted EBITDA and Credit Agreement EBITDA and Credit Agreement total leverage ratio:

    Six Months Ended June 30, Year Ended Dec 31,
    $ million

    2024

    2023

    2023

    Net sales

    $

    2,545.4

     

    $

    2,566.1

     

    $

    5,062.4

     

     
    Net income

    $

    29.0

     

    $

    89.2

     

    $

    142.2

     

    Interest expense, net

     

    95.6

     

     

    77.8

     

     

    154.4

     

    Income taxes

     

    17.2

     

     

    26.9

     

     

    60.8

     

    Depreciation and amortization

     

    61.8

     

     

    56.7

     

     

    113.3

     

    EBITDA

     

    203.6

     

     

    250.6

     

     

    470.7

     

    Amortization of SaaS implementation costs

     

    12.3

     

     

    -

     

     

    6.0

     

    Expenses related to Restructuring Program

     

    65.5

     

     

    -

     

     

    -

     

    Expenses related to Transformation Program

     

    9.4

     

     

    37.4

     

     

    54.2

     

    Digital technology program costs

     

    17.0

     

     

    10.5

     

     

    32.1

     

    (Gain) loss on extinguishment of debt

     

    10.5

     

     

    -

     

     

    (1.0

    )

    Korea tax settlement

     

    -

     

     

    -

     

     

    8.6

     

    Adjusted EBITDA

    $

    318.3

     

    $

    298.5

     

    $

    570.6

     

    Adjusted EBITDA margin

     

    12.5

    %

     

    11.6

    %

     

    11.3

    %

     
    Interest income

     

    6.5

     

     

    5.1

     

     

    11.5

     

    Inventory write-downs

     

    11.4

     

     

    16.9

     

     

    28.5

     

    Share-based compensation expenses

     

    23.7

     

     

    22.0

     

     

    48.0

     

    Other expenses (3)

     

    7.6

     

     

    3.5

     

     

    11.5

     

    Credit Agreement EBITDA

    $

    367.5

     

    $

    346.0

     

    $

    670.1

     

    Credit Agreement Total Debt (4)

    $

    2,581.1

     

    Credit Agreement Total Leverage Ratio 3.9x
     
    (1) Based on interim income tax reporting rules, these expenses are not considered discrete items. The tax effect of the adjustments between our U.S. GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s).
     
    (2) Excludes tax (benefit)/expense as follows:
    Three Months Ended June 30, Six Months Ended June 30,
    $ million

    2024

    2023

    2024

    2023

    Expenses related to Restructuring Program

    $

    (15.7

    )

    $

    -

     

    $

    (20.2

    )

    $

    -

     

    Expenses related to Transformation Program

     

    (0.5

    )

     

    (2.5

    )

     

    (2.5

    )

     

    (8.5

    )

    Digital technology program costs

     

    0.1

     

     

    (0.5

    )

     

    (2.0

    )

     

    (0.7

    )

    Loss on extinguishment of debt

     

    (2.6

    )

     

    -

     

     

    (2.6

    )

     

    -

     

    Total income tax adjustments

    $

    (18.7

    )

    $

    (3.0

    )

    $

    (27.3

    )

    $

    (9.2

    )

     
     
     
    Three Months Ended June 30, Six Months Ended June 30,
    $ per share

    2024

    2023

    2024

    2023

    Expenses related to Restructuring Program

    $

    (0.15

    )

    $

    -

     

    $

    (0.20

    )

    $

    -

     

    Expenses related to Transformation Program

     

    -

     

     

    (0.02

    )

     

    (0.02

    )

     

    (0.09

    )

    Digital technology program costs

     

    -

     

     

    (0.01

    )

     

    (0.02

    )

     

    (0.01

    )

    Loss on extinguishment of debt

     

    (0.03

    )

     

    -

     

     

    (0.03

    )

     

    -

     

    Total income tax adjustments (5)

    $

    (0.18

    )

    $

    (0.03

    )

    $

    (0.27

    )

    $

    (0.09

    )

     
    (3) Other expenses include certain non-cash items such as bad debt expense, unrealized foreign currency gains and losses, and other gains and losses
     
    (4) Represents the outstanding principal amount of total debt as of the respective period end
     
    (5) Amounts may not total due to rounding

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240730118998/en/

    Get the next $HLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLF

    DatePrice TargetRatingAnalyst
    3/21/2025$7.50 → $14.00Neutral → Buy
    DA Davidson
    8/1/2024$16.00 → $17.00Buy
    B. Riley Securities
    9/14/2023$13.50Neutral
    DA Davidson
    6/7/2023$13.00Neutral
    Mizuho
    2/3/2023$14.00Underperform
    BofA Securities
    7/12/2022$26.00Hold → Buy
    Jefferies
    5/17/2022Buy → Hold
    Argus
    5/4/2022$60.00 → $26.00Buy → Hold
    Jefferies
    More analyst ratings

    $HLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Herbalife Nutrition upgraded by DA Davidson with a new price target

      DA Davidson upgraded Herbalife Nutrition from Neutral to Buy and set a new price target of $14.00 from $7.50 previously

      3/21/25 8:38:07 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • B. Riley Securities reiterated coverage on Herbalife Nutrition with a new price target

      B. Riley Securities reiterated coverage of Herbalife Nutrition with a rating of Buy and set a new price target of $17.00 from $16.00 previously

      8/1/24 8:12:23 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • DA Davidson initiated coverage on Herbalife Nutrition with a new price target

      DA Davidson initiated coverage of Herbalife Nutrition with a rating of Neutral and set a new price target of $13.50

      9/14/23 7:19:53 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL

      Certified Method Enhances Global Botanical Quality and Safety Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)—a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-app

      6/11/25 7:14:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife to Participate in MicroCap Rodeo Conference on June 4

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced John DeSimone, Chief Financial Officer, will participate in a fireside chat at the MicroCap Rodeo Conference on Wednesday, June 4, 2025 at 9:30 a.m. ET (6:30 a.m. PT). The webcast will be available at the following link: https://www.webcaster4.com/Webcast/Page/3119/52530 The webcast will also be available under the Investor Relations section of Herbalife's website at https://ir.herbalife.com/. A replay of the webcast will be available at the same website following the completion of the event and for six months thereafter. For more details about the MicroCap Rodeo Conference in New

      5/27/25 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Reports Q1 Net Sales at Midpoint of Guidance Range, Net Sales Growth Excluding FX Headwinds1; Q1 Adjusted EBITDA2 Exceeds Guidance; Updates Full-Year Guidance

      Herbalife Ltd. (NYSE:HLF) today reported financial results for the first quarter ended March 31, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430667438/en/ "Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth," Stephan Gratziani, President and incoming CEO (effective May 1 '25). Highlights First Quarter 2025 Net sales of $1.2 billion at midpoint of guidance range Down 3.4% vs. Q1 ‘24 Includes 480 basis points of FX headwinds Up 1.4% year-over-year on constant cu

      4/30/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      6/9/25 6:00:12 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/23/25 4:01:25 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,650 worth of shares (5,000 units at $6.73) and was granted 21,857 shares, increasing direct ownership by 20% to 161,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/6/25 8:19:33 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      6/9/25 6:00:12 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/23/25 4:01:25 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • New insider Levy Robert claimed ownership of 449,358 shares (SEC Form 3)

      3 - HERBALIFE LTD. (0001180262) (Issuer)

      5/12/25 7:39:33 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    SEC Filings

    See more
    • Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HERBALIFE LTD. (0001180262) (Filer)

      4/30/25 4:40:01 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Herbalife Ltd.

      10-Q - HERBALIFE LTD. (0001180262) (Filer)

      4/30/25 4:16:43 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Herbalife Ltd.

      SCHEDULE 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      4/30/25 11:12:30 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

      SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      11/14/24 4:11:11 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Herbalife Ltd.

      SC 13G - HERBALIFE LTD. (0001180262) (Subject)

      11/13/24 4:01:31 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

      SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      11/13/24 12:49:27 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Financials

    Live finance-specific insights

    See more
    • Herbalife Reports Q1 Net Sales at Midpoint of Guidance Range, Net Sales Growth Excluding FX Headwinds1; Q1 Adjusted EBITDA2 Exceeds Guidance; Updates Full-Year Guidance

      Herbalife Ltd. (NYSE:HLF) today reported financial results for the first quarter ended March 31, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430667438/en/ "Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth," Stephan Gratziani, President and incoming CEO (effective May 1 '25). Highlights First Quarter 2025 Net sales of $1.2 billion at midpoint of guidance range Down 3.4% vs. Q1 ‘24 Includes 480 basis points of FX headwinds Up 1.4% year-over-year on constant cu

      4/30/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife to Announce First Quarter 2025 Results on April 30

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, will release its first quarter 2025 financial results after the close of trading on the NYSE on Wednesday, April 30, 2025. On the same day, at 5:30 p.m. ET (2:30 p.m. PT), Herbalife's senior management team will host an audio webcast and conference call to discuss its recent financial results. The audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/bd8j8th6 Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link: https://register-conf.media-server.com/register/BI1210

      4/1/25 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Reports Q4 Net Sales at High End of Guidance, Q4 and Full-Year Net Sales Growth Excluding FX Headwinds1; Q4 Adjusted EBITDA2 Exceeds Guidance

      Stephan Gratziani Appointed CEO; Michael Johnson Named Executive Chairman Herbalife Ltd. (NYSE:HLF) today reported financial results for the fourth quarter and year ended December 31, 2024: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219267078/en/ "With three consecutive quarters of new distributor growth, a new incoming CEO and significantly improved Adjusted EBITDA2 margins, we enter 2025 with strong momentum." - Michael Johnson, Chairman and CEO Highlights Fourth Quarter 2024 Net sales of $1.2 billion, down 0.6% vs. Q4 '23 and at high end of guidance range Includes 330 basis points of FX headwinds Up 2.7% year-o

      2/19/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Leadership Updates

    Live Leadership Updates

    See more
    • Herbalife Welcomes Lynda Cloud to its Board of Directors

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the election of Lynda Cloud to its Board of Directors, effective April 23, 2025. This appointment reflects Herbalife's continued commitment to innovation, digital transformation, and personalized wellness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425107883/en/Herbalife Welcomes Lynda Cloud to the Board of Directors Lynda Cloud's decades of leadership across education, technology, and health sectors make her uniquely equipped to support Herbalife's next chapter. Her deep expertise in digital learning, consumer experie

      4/25/25 5:12:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Appoints Stephan Gratziani as Chief Executive Officer

      Current CEO Michael Johnson Transitions to Executive Chairman Herbalife Ltd. (NYSE:HLF) today announced its Board of Directors has appointed President, Stephan Gratziani as Chief Executive Officer (CEO) effective May 1, 2025. Michael Johnson, current CEO and Chairman of the Board, will transition to Executive Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219653469/en/Herbalife appoints Stephan Gratziani as Chief Executive Officer (Photo: Business Wire) As a former Herbalife independent distributor, Mr. Gratziani built and grew his international business into one of the top global distributorships. For 32 years, he

      2/19/25 4:05:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Expands Board of Directors with Appointment of Perkins Miller

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today welcomed experienced e-commerce and media technology executive Perkins Miller to its board of directors. Miller's appointment as an independent director is effective June 26, 2024. "Perkins brings valuable, proven expertise in leading large-scale e-commerce, technology and sports enterprises, which will be a great asset to our Board as the Company continues to grow and transform," said Michael Johnson, Chairman and CEO of Herbalife. Miller is the CEO of Fandom, the world's largest fan platform where fans immerse themselves in imagined worlds across entertainment and gaming, where he has trans

      6/26/24 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care